SCHEMBL6591833

SCHEMBL6591833

C/C=C1\c2ccccc2C(=O)N1c1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTT P42858 1/20 0.46
APP P05067 2/20 0.43
MAPT P10636 2/20 0.43
SNCA P37840 2/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
BCHE P06276 1/20 0.42
SCN2A Q99250 3/20 0.41
LMNA P02545 2/20 0.41
CA9 Q16790 2/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6593962 1.00 KDM4E (0.51) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL6591136 1.00 KDM4E (0.51) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL11619942 0.82 KDM4E (0.70) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL6589327 0.75 ALDH1A1 (0.56) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL18196230 0.70 CASP3 (0.55) KDM4EALDH1A1HPGDHTTAPP
SCHEMBL15267393 0.69 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL28373918 0.68 ITGA4 (0.49) KDM4EALDH1A1HPGDAPPMAPT
SCHEMBL2348974 0.68 CES1 (0.73) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL4649471 0.68 KMT2A (0.78) ALDH1A1HTTKMT2AMEN1SCN2A
SCHEMBL30089821 0.67 ALDH1A1 (0.70) KDM4EALDH1A1HPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0703232-B1 2,3-Dihydro-1H-isoindole derivates, a process for their preparation and their use as serotonin reuptake inhibitors AVENTIS PHARMA INC (US) 2004-06-30 EP claimed